by The global Viral Vectors & Plasmid DNA Manufacturing market size is expected to surpass around US$ 3701.47 million by 2027 and the market is expected to garner growth at a CAGR of 14.08% over the forecast period 2021 to 2027.
The Viral Vectors & Plasmid DNA Manufacturing market report covers a detailed analysis for the historic period 2017-2020, considering 2021 as the base year and forecast (growth) for 2021-2027.
Get the sample copy of this report@ https://www.precedenceresearch.com/sample/1012
Growth Factors
Viral vectors have become ideal choice for gene transfer due to their efficient gene delivery, high transfection efficiency and stable gene expression. Further, upsurge in registration of clinical trials on viral vector-mediated gene therapy is stimulating inclination for viral vectors in gene transfer. Growing pervasiveness of target disorders and diseases, the accessibility of funding for gene therapy development, current research into viral vector-based cell and gene therapies and efficacy of viral vectors in gene therapy delivery are together supporting the market growth. Unexploited latent in emergent markets is projected to provide worthwhile growth opportunities for participants in this market. Furthermore, groundbreaking development in the vaccinology is fuelling the demand of these vectors to greater extent. Great amount of clinical and preclinical studies assessing the prospective of vectors in these cutting-edge therapies have exhibited favorable results. As a result of this, several investors are attracted towards this area which is making plasmid and viral vector manufacturing market a vigorous sector of investment. Further, it is inspiring fortunate funding activities from both the public and private sectors.
Market Report Scope
| Report Highlights | Details |
| Market Size In 2027 | USD 3701.47 million |
| Growth Rate | CAGR of 14.08% From 2020 to 2027 |
| Base Year | 2020 |
| Historic data | 2017 to 2020 |
| Forecast Period | 2021 to 2027 |
Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1012
Market Overview
A recent study by Precedence Research on the Viral Vectors & Plasmid DNA Manufacturing market offers a forecast for 2021 and 2027. The study analyzes crucial trends that are currently determining the growth of the Viral Vectors & Plasmid DNA Manufacturing market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of Viral Vectors & Plasmid DNA Manufacturing. The study also provides the dynamics that are responsible for influencing the future status of the Viral Vectors & Plasmid DNA Manufacturing market over the forecast period.
A detailed assessment of the Viral Vectors & Plasmid DNA Manufacturing market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the Viral Vectors & Plasmid DNA Manufacturing market along with their product portfolio enhances the reliability of this comprehensive research study.
Report Highlights
- Presently, around two-thirds of the gene therapy research is dedicated to oncology. These different facts have backed the governance of cancer segment over other disease segments
- Extensive progress made in gene and cell therapy research since the early 1970s and 1980s has accelerated the adoption rate of plasmids and viral vectors for their use in these modern therapies
- Pharmaceutical and biopharmaceutical companies are expected to collect major share of the global vector market. This is because of the effective launch of viral vector gene therapies and a vigorous pipeline of such therapies that helps growth of pharmaceutical and biopharmaceutical companies during near future.
- Presently, U.S. and Europe have seemed as vector manufacturing centers despite of the fact that the first 3 gene therapy candidates were granted in Asian countries
Regional Snapshots
About 68% of the total international active clinical studies for gene therapies are proceeding in North America despite of the fact that the first 3 gene therapy candidates (Oncorine®, Gendicine® andRexin-G®) were accepted in Asia Pacific. During coming years, Asia Pacific is anticipated to grow at the fastest pace viral vector manufacturing market. Spurring research activities to unveil innovative gene therapies in the unexploited markets of this region are projected to support this tremendous growth in near future.
OBJECTIVES OF THE STUDY
- To analyze and forecast the electric motor market, in terms of value and volume
- To provide information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
- To define, segment, and project the size of the global electric motor market on the product type, end-use and other segments
- To project the size of the market, with respect to five main regions, namely, North America, Europe, Asia Pacific (APAC), the Middle East & Africa, and South America, with their key countries
- To strategically analyze micro markets with respect to individual growth trends, growth prospects, and their contribution to the total market
- To analyze opportunities in the market for stakeholders and provide a competitive landscape of the market leaders
- To strategically profile key players and comprehensively analyze their core competencies
- To track and analyze research & development (R&D) and competitive developments such as joint ventures, mergers & acquisitions, and new product developments in the electric motor market
Research Methodology
- Market estimate for 2020
- Average selling price (ASP) per region for specific product type
- Filtrations and assortment of gathered data, to estimate the base year (2021) market size for the country
- Gathering data from company websites, annual reports, white papers, financial reports, broker reports, investor presentations, and SEC filings
- National government documents, statistical databases
- News articles, press releases, and webcasts specific to companies operating in the market
- Country wise analysis through internal and external proprietary databases, and relevant patent and regulatory databases
- Determination of market penetration by country
Major Players Covered in this Report
The updated market research report on electric motor market allows the buyers and manufacturers to stay updated with the current market trends, ongoing happenings, and a clear picture on the market scenario. List of key players included in the research report will help the market vendors to know their market position and plan more operational strategies to gain topmost position among other players. The report offers crucial company information on each market player, such as company profile, financial information, and recently adopted growth strategies. This will help other existing players and the new entrants to plan strategies and establish their presence in the market.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
- Company Overview
- Company Market Share/Positioning Analysis
- Product Offerings
- Financial Performance
- Recent Initiatives
- Key Strategies Adopted by Players
- Vendor Landscape
- List of Suppliers
- List of Buyers
Major key players operating in the market are
- Novasep
- Aldevron
- MerckWaismanBiomanufacturing
- Creative Biogene
- The Cell and Gene Therapy Catapult
- Cobra Biologics
- uniQure N.V.
- Addgene
- FUJIFILM Holdings Corporation
- Oxford Biomedicaplc
- Takara Bio Inc.
Segments Covered in the Report
By Vector Type
- Adenovirus
- Plasmid DNA
- Lentivirus
- Retrovirus
- AAV
- Others
By Application
- Gene Therapy
- Antisense &RNAi
- Cell Therapy
- Vaccinology
By Workflow
- Upstream Processing
- Vector Recovery/Harvesting
- Vector Amplification & Expansion
- Downstream Processing
- Fill-finish
- Purification
By End-User
- Biopharmaceutical and Pharmaceutical Companies
- Research Institutes
By Disease
- Genetic Disorders
- Cancer
- Infectious Diseases
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Why should you invest in this report?
If you are aiming to enter the global Viral Vectors & Plasmid DNA Manufacturing market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for Viral Vectors & Plasmid DNA Manufacturing are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2027, so that you can plan your strategies to enter this market accordingly. Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
TABLE OF CONTENT
Buy this Research Report study@ https://www.precedenceresearch.com/checkout/1012
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333
About Us
Prece
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type
7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type, 2020-2027
7.1.1. Adenovirus
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Lentivirus
7.1.3.1. Market Revenue and Forecast (2016-2027)
7.1.4. Retrovirus
7.1.4.1. Market Revenue and Forecast (2016-2027)
7.1.5. AAV
7.1.5.1. Market Revenue and Forecast (2016-2027)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type
8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type, 2020-2027
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Antisense &RNAi
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Cell Therapy
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Vaccinology
8.1.4.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type
9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type, 2020-2027
9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Downstream Processing (Fill-finish, Purification)
9.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type
10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type, 2020-2027
10.1.1. Biopharmaceutical and Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease
11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease, 2020-2027
11.1.1. Genetic Disorders
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Cancer
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Forecast (2016-2027)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2016-2027)
Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.5. Market Revenue and Forecast, by Disease (2016-2027)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.7. Market Revenue and Forecast, by Disease (2016-2027)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.9. Market Revenue and Forecast, by Disease (2016-2027)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.5. Market Revenue and Forecast, by Disease (2016-2027)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.7. Market Revenue and Forecast, by End-User (2016-2027)
12.2.8. Market Revenue and Forecast, by Disease (2016-2027)
12.2.8.1. Market Revenue and Forecast, by Raw Material (2016-2027)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.9.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.9.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.10. Market Revenue and Forecast, by End-User (2016-2027)
12.2.11. Market Revenue and Forecast, by Disease (2016-2027)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.12.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.12.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.12.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.13. Market Revenue and Forecast, by Disease (2016-2027)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.14.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.14.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.14.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.15. Market Revenue and Forecast, by Disease (2016-2027)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.5. Market Revenue and Forecast, by Disease (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.7. Market Revenue and Forecast, by Disease (2016-2027)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.9. Market Revenue and Forecast, by Disease (2016-2027)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.10.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.10.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.10.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.10.5. Market Revenue and Forecast, by Disease (2016-2027)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.11.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.11.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.11.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.11.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.7. Market Revenue and Forecast, by Disease (2016-2027)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.9. Market Revenue and Forecast, by Disease (2016-2027)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.10.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.10.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.10.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.10.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.11.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.11.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.11.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.11.5. Market Revenue and Forecast, by Disease (2016-2027)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.5. Market Revenue and Forecast, by Disease (2016-2027)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.7. Market Revenue and Forecast, by Disease (2016-2027)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.8.5. Market Revenue and Forecast, by Disease (2016-2027)
Chapter 13. Company Profiles
13.1. Novasep
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Aldevron
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck Waisman Biomanufacturing
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Creative Biogene
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Cell and Gene Therapy Catapult
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Cobra Biologics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. uniQure N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Addgene
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FUJIFILM Holdings Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Oxford Biomedicaplc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. Takara Bio Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
dence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
For Latest Update Follow Us:
https://www.linkedin.com/company/precedence-research/
